Severe Marrow Failure With Clonal T-cell Large Granular Lymphocytic Proliferation in Myelodysplastic Syndrome: A Case Report

Worsening cytopenias in patients with myelodysplastic syndrome (MDS) may reflect disease progression or an additional marrow failure process. We report a 72-year-old man with intermediate-risk MDS, metastatic hormone-sensitive prostate adenocarcinoma, dialysis-dependent end-stage renal disease (ESRD), and chronic transfusion dependence who presented with one week of progressive weakness and altered mental status. Multilineage cytopenias had progressed over more than three years. Admission studies showed a white blood cell count (WBC) of 0.4 × 10³/µL, hemoglobin of 8.4 g/dL, platelet count of 6 × 10³/µL, and absolute neutrophil count (ANC) of 0.1 × 10³/µL. Marrow examination demonstrated hypocellularity, relative expansion of T-cell large granular lymphocytes, and clonal T-cell receptor beta rearrangement. Repeat marrow cellularity was below 5%, supporting a very severe aplastic anemia phenotype, although the contribution of the T-cell clone remained uncertain. Intermittent fever, splenomegaly, hyperferritinemia, and elevated soluble interleukin-2 receptor alpha and C-X-C motif chemokine ligand 9 (CXCL9) prompted evaluation for hemophagocytic lymphohistiocytosis (HLH). The treating team described HLH-like hyperinflammation; available documentation did not establish the five HLH-2004 criteria. Treatment included transfusions, filgrastim, erythropoiesis-stimulating therapy, thrombopoietin receptor agonists, intravenous immunoglobulin (IVIG), dexamethasone, cyclophosphamide, and subsequently horse antithymocyte globulin, cyclosporine, and eltrombopag. A necrotic lower extremity wound, Escherichia coli and vancomycin-resistant Enterococcus faecium (VRE) bacteremia, recurrent respiratory failure, cardiac dysfunction, septic shock, and progressive multiorgan dysfunction complicated management. No hematologic recovery occurred before death on hospital day 62 after transition to comfort-focused care. This case illustrates the need to reassess severe cytopenias in established MDS while distinguishing clonal T-cell proliferation from confirmed leukemia and weighing immunosuppression against infection and limited organ reserve.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-16
DOI
https://doi.org/10.7759/cureus.119772
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Severe Marrow Failure With Clonal T-cell Large Granular Lymphocytic Proliferation in Myelodysplastic Syndrome: A Case Report

Ikken Aisin
Cureus
Acute Myeloid Leukemia Research
article

Severe Marrow Failure With Clonal T-cell Large Granular Lymphocytic Proliferation in Myelodysplastic Syndrome: A Case Report

Ikken Aisin
article en

Abstract

Worsening cytopenias in patients with myelodysplastic syndrome (MDS) may reflect disease progression or an additional marrow failure process. We report a 72-year-old man with intermediate-risk MDS, metastatic hormone-sensitive prostate adenocarcinoma, dialysis-dependent end-stage renal disease (ESRD), and chronic transfusion dependence who presented with one week of progressive weakness and altered mental status. Multilineage cytopenias had progressed over more than three years. Admission studies showed a white blood cell count (WBC) of 0.4 × 10³/µL, hemoglobin of 8.4 g/dL, platelet count of 6 × 10³/µL, and absolute neutrophil count (ANC) of 0.1 × 10³/µL. Marrow examination demonstrated hypocellularity, relative expansion of T-cell large granular lymphocytes, and clonal T-cell receptor beta rearrangement. Repeat marrow cellularity was below 5%, supporting a very severe aplastic anemia phenotype, although the contribution of the T-cell clone remained uncertain. Intermittent fever, splenomegaly, hyperferritinemia, and elevated soluble interleukin-2 receptor alpha and C-X-C motif chemokine ligand 9 (CXCL9) prompted evaluation for hemophagocytic lymphohistiocytosis (HLH). The treating team described HLH-like hyperinflammation; available documentation did not establish the five HLH-2004 criteria. Treatment included transfusions, filgrastim, erythropoiesis-stimulating therapy, thrombopoietin receptor agonists, intravenous immunoglobulin (IVIG), dexamethasone, cyclophosphamide, and subsequently horse antithymocyte globulin, cyclosporine, and eltrombopag. A necrotic lower extremity wound, Escherichia coli and vancomycin-resistant Enterococcus faecium (VRE) bacteremia, recurrent respiratory failure, cardiac dysfunction, septic shock, and progressive multiorgan dysfunction complicated management. No hematologic recovery occurred before death on hospital day 62 after transition to comfort-focused care. This case illustrates the need to reassess severe cytopenias in established MDS while distinguishing clonal T-cell proliferation from confirmed leukemia and weighing immunosuppression against infection and limited organ reserve.

Cureus
University of California, San Francisco (US), Community Regional Medical Center (US)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon